Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Genmab and AbbVie clarified that in the Phase 3 EPCORE DLBCL-1 trial, overall survival (OS) was the sole U.S. primary endpoint and it was not met (no statistically significant OS improvement), despite earlier topline results. The study evaluated subcutaneous epcoritamab monotherapy versus investigator’s choice chemotherapy (R-GemOx or BR) in relapsed/refractory DLBCL patients ineligible for autologous stem cell transplant. Additional data will be submitted for publication, while Genmab/AbbVie continue epcoritamab development in other EPCORE programs.

Analysis

The market impact is less about near-term sales and more about a reduced probability of epcoritamab becoming a multi-line franchise. That matters far more for GMAB than ABBV: Genmab’s valuation is still tethered to platform optionality, so any evidence that the asset cannot clearly beat standard-of-care on hard survival endpoints should compress the pipeline multiple, even if current approved revenue remains intact. For AbbVie, the earnings hit is muted, but this removes one of the cleaner oncology growth narratives that could have helped offset slower mature immunology growth.

Second-order, this is constructive for entrenched comparators rather than a direct win for any single named competitor. If payers and physicians see less confidence in a chemo-free bispecific path in transplant-ineligible DLBCL, the burden of proof shifts back to CAR-T in fitter patients and to chemoimmunotherapy where logistics and safety are predictable; that is a negative read-through for the broader bispecific class and for companies trying to push earlier-line displacement. The key mechanism is commercial: convenience alone rarely supports premium pricing if OS ambition gets diluted.

The catalyst path is over the next 1-3 months when full data are dissected and management frames DLBCL-2 / DLBCL-4. If subgroup or duration-of-response signals are weak, the stock can keep drifting lower as analysts cut peak-sales assumptions; if earlier-line data surprise positively in 2026, this could be a temporary de-risking rather than a full reset. The contrarian view is that the move may be overdone for ABBV, because this is not a core earnings driver, but probably underdone for GMAB where every failed expansion attempt reduces the implied value of the DuoBody platform.

Key Decisions for Investors

• Short GMAB on any post-release bounce; thesis is multiple compression from reduced peak-sales optionality, with 1-3 month downside if publication commentary confirms no compelling subgroup rescue. Falsifier: clear positive earlier-line DLBCL-2 data in 2026.
• Avoid overreacting in ABBV; use weakness only as a relative-value opportunity vs. higher-beta biotech rather than an outright short. The event is strategically negative, but the direct EPS impact is likely too small to justify standalone bearish positioning.
• Pair trade: long ABBV / short GMAB for 2-6 weeks to isolate idiosyncratic disappointment against AbbVie’s diversified cash flow. Risk/reward favors the spread if the market applies a platform penalty to Genmab while leaving AbbVie largely unchanged.
• Set an alert around upcoming DLBCL-2 readout and journal publication; if response-depth data are also soft, increase conviction on a longer-dated short GMAB into the next catalyst window. If DLBCL-2 is positive, cover quickly as the thesis shifts from franchise failure to indication-specific setback.